| Literature DB >> 22276048 |
R Passerini1, Tl Ghezzi, Mt Sandri, D Radice, R Biffi.
Abstract
BACKGROUND: Bloodstream infections (BSIs) are one of the major life-threatening infectious conditions in cancer patients and are responsible for prolonged hospital stays, high healthcare costs and significant mortality. Several clinical trials have reported an improved survival in patients treated with appropriate empirical broad-spectrum antibiotic therapy. Early detection of pathogens and determination of their susceptibility are essential for the optimization of treatment. Variability between hospitals is substantial and requires the individual analysis of local trends. The aim of this study is to assess the local epidemiology of BSI in a single cancer centre over a 10-year period.Entities:
Year: 2011 PMID: 22276048 PMCID: PMC3223944 DOI: 10.3332/ecancer.2011.191
Source DB: PubMed Journal: Ecancermedicalscience ISSN: 1754-6605
Blood cultures data
| All BCs performed | 13,058 | 7,050 | 6,008 |
| Suspicious infective episodes | 4,308 (100) | 1,929 (100) | 2,379 (100) |
| Number BC/infective episodes | 3.03 | 3.65 | 2.52 |
| Patients | 2,976 | 1,047 | 1,929 |
| CVC-related infections | 2,861 (66.4) | 1,598 (82.8) | 1,263 (53.1) |
| Non CVC-related infections | 1,447 (33.6) | 331 (17.2) | 1,116 (46.9) |
| Negative BC | 3,568 (82.8) | 1,571 (81.4) | 1,997 (83.9) |
| Positive BC | 740 (17.2) | 358 (18.6) | 382 (16.1) |
| Gram-positive | 436 (58.9) | 225 (62.8) | 211 (55.2) |
| Gram-negative | 255 (34.5) | 116 (32.4) | 139 (36.4) |
| Anaerobes | 20 (2.7) | 7 (2) | 13 (3.4) |
| Fungi | 15 (2) | 1 (0.3) | 14 (3.7) |
| Other pathogens | 14 (1.9) | 9 (2.5) | 5 (1.3) |
BC, blood cultures; CVC,central venous catheter.
Figure 1:Main isolates in blood culture from 1999 to 2008 (%). CoNS: coagulase negative staphylococci.
Percent of gram-positive, gram-negative and main isolates in BC of medical oncology patients
| Gram-positive | 62.2 | 81.2 | 58.3 | 75.8 | 76.1 | 63.5 | 57.5 | 53.9 | 57.1 | 36.4 | −0.75 | |
| Gram-negative | 37.8 | 18.8 | 38.9 | 18.2 | 21.7 | 28.9 | 35.0 | 30.8 | 28.6 | 63.6 | 0.22 | 0.533 |
| 14.7 | 8.5 | 13.5 | 10.3 | 8.5 | 10.6 | 10.8 | 2.8 | 13.2 | 13.2 | −0.12 | 0.750 | |
| Other | 13.1 | 9.1 | 16.2 | 12.8 | 13.4 | 14.1 | 20.3 | 18.3 | 7.4 | 14.5 | 0.28 | 0.425 |
| 6.6 | 1.4 | 5.4 | 2.6 | 4.9 | 2.4 | 4.1 | 5.6 | 4.4 | 10.5 | 0.25 | 0.489 | |
| 36.1 | 45.2 | 43.2 | 46.2 | 40.2 | 40.0 | 40.6 | 52.1 | 38.2 | 34.2 | −0.24 | 0.511 | |
| 8.2 | 6.7 | 6.8 | 6.4 | 11.0 | 8.2 | 6.8 | 4.2 | 1.5 | 5.3 | −0.57 | 0.083 | |
CoNS, coagulase negative staphylococci.
Figure 2Gram-positives and gram-negatives isolated in blood cultures from medical oncology patients from 1999 to 2008 (%).
Annual incidence (per 1000 admissions) of BCs and isolates, 1999–2008, whole series
| All BCs performed | 104.0 | 104.6 | 86.2 | 83.1 | 75.4 | 74.6 | 62.4 | 67.9 | 70.0 | 71.8 | −0.87 | |
| Suspicious infective episodes | 34.7 | 35.8 | 29.7 | 26.7 | 29.6 | 25.5 | 22.4 | 21.2 | 25.5 | 25.0 | −0.86 | |
| BC/infective episodes | 3.2 | 3.0 | 3.1 | 3.4 | 2.6 | 3.0 | 2.9 | 3.4 | 2.8 | 3.0 | −0.31 | 0.377 |
| Patients | 22.9 | 23.9 | 19.6 | 18.3 | 22.6 | 18.7 | 15.9 | 16.7 | 19.9 | 18.6 | −0.58 | 0.082 |
| CVC-related infections | 25.3 | 26.5 | 20.5 | 16.8 | 17.4 | 16.6 | 14.5 | 12.4 | 13.0 | 14.6 | −0.89 | |
| Non CVC-related infections | 9.5 | 9.3 | 9.2 | 9.9 | 12.2 | 8.9 | 7.9 | 8.7 | 12.4 | 10.4 | 0.11 | 0.751 |
| Negative BC | 29.0 | 30.0 | 24.6 | 21.9 | 24.2 | 20.3 | 18.4 | 17.6 | 21.7 | 20.8 | −0.79 | |
| Positive BC | 5.8 | 5.5 | 5.1 | 4.8 | 5.4 | 5.2 | 4.0 | 3.6 | 3.6 | 4.2 | −0.83 | |
| Gram-positive | 3.2 | 3.9 | 3.1 | 3.0 | 3.6 | 3.0 | 2.3 | 2.1 | 1.9 | 2.1 | −0.87 | |
| Gram-negative | 2.6 | 1.4 | 1.8 | 1.5 | 1.6 | 1.5 | 1.5 | 1.9 | 1.0 | 1.9 | −0.09 | 0.790 |
| Anaerobes | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.4 | 0.0 | 0.1 | 0.2 | 0.1 | 0.33 | 0.346 |
| Fungi | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.2 | 0.45 | 0.192 |
| Other pathogens | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.0 | 0.48 | 0.157 |
BC, blood culture; CVC, central venous catheter.
p-values <0.05 are italicised.
Annual incidence (per 1,000 admissions) of BCs and isolates, 1999–2008, medical oncology patients
| All BCs performed | 210.7 | 159.6 | 120.6 | 92.7 | 88.9 | 80.4 | 63.7 | 48.1 | 65.1 | 72.2 | −0.89 | |
| Suspicious infective episodes | 36.2 | 26.6 | 17.9 | 14.5 | 15.6 | 25.4 | 10.7 | 10.1 | 12.6 | 12.2 | −0.82 | |
| Patients | 61.8 | 46.0 | 31.7 | 23.9 | 27.2 | 25.4 | 19.9 | 14.3 | 19.5 | 20.3 | −0.88 | |
| CVC-related infections | 50.3 | 38.6 | 25.2 | 18.8 | 20.5 | 19.4 | 14.8 | 10.9 | 14.9 | 15.3 | −0.85 | |
| Non CVC-related infections | 11.5 | 7.4 | 6.5 | 5.9 | 6.7 | 6.0 | 5.0 | 3.3 | 4.5 | 5.0 | −0.87 | |
| Negative BC | 53.5 | 40.8 | 26.6 | 19.6 | 20.7 | 18.9 | 15.3 | 11.3 | 16.3 | 16.4 | −0.88 | |
| Positive BC | 8.6 | 5.3 | 5.0 | 4.3 | 6.4 | 6.5 | 4.6 | 3.1 | 3.2 | 3.9 | −0.72 | |
| Gram-positive | 5.3 | 4.3 | 3.0 | 3.4 | 4.9 | 4.1 | 2.6 | 1.7 | 1.8 | 1.4 | −0.84 | |
| Gram-negative | 3.2 | 0.1 | 1.8 | 0.7 | 1.4 | 1.9 | 1.6 | 0.9 | 0.9 | 2.5 | 0.04 | 0.920 |
| Anaerobes | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.2 | 0.0 | 0.1 | 0.1 | 0.0 | 0.10 | 0.786 |
| Fungi | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.06 | 0.873 |
| Other pathogens | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.3 | 0.0 | 0.59 | 0.073 |
BC, blood culture; CVC, central venous catheter.
p-values <0.05 are italicised.